Drug updated on 10/24/2024
| Dosage Form | Injection (subcutaneous; 30 mg/3 mL [10 mg/mL], 153 mg/1.7 mL [90 mg/mL]) |
| Drug Class | Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- BCMA-targeting agents showed an Overall Response Rate (ORR) ranging from 25% to 100%, while non-BCMA-targeting agents showed an ORR range of 60% to 100%.
- Complete Response/Stringent Complete Response (CR (complete response)/sCR) rates for BCMA-targeting agents ranged from 7% to 38%, compared to 19% to 63% for non-BCMA-targeting agents.
- Very Good Partial Response (VGPR) rates ranged from 5% to 92% for BCMA-targeting agents and from 21% to 65% for non-BCMA-targeting agents.
- Cytokine release syndrome was observed in 17% to 82% of patients.
- Anemia, neutropenia, and thrombocytopenia were reported in 5% to 52%, 12% to 75%, and 14% to 42% of patients, respectively.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tecvayli (teclistamab-cqyv) Prescribing Information. | 2024 | Janssen Biotech, Inc., Horsham, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review | 2023 | Antibodies |